Literature DB >> 16690498

Natural history of thromboembolism in AL amyloidosis.

Christine S Halligan1, Martha Q Lacy, S Vincent Rajkumar, Angela Dispenzieri, Thomas E Witzig, John A Lust, Rafael Fonseca, Morie A Gertz, Robert A Kyle, Rajiv K Pruthi.   

Abstract

To determine the natural history of thromboembolism in patients with biopsy-proven AL amyloidosis, medical records of 2,132 patients evaluated at Mayo Clinic between 1975 and 2000 were reviewed. Forty patients (21 male) were found to have objectively documented thromboembolism. The median age was 65 years. Four patients had a monoclonal gammopathy of undetermined significance, 20 had an unspecified plasma cell proliferative disorder, 11 had multiple myeloma, and 1 had Waldenström macroglobulinemia. Twelve patients had cardiac amyloid, and 20 had renal amyloid. Neither the extent of the amyloid nor the type of monoclonal protein was predictive of the development of thromboembolic events. Thromboembolism preceded the diagnosis of AL amyloidosis in 11 patients, occurred at the time of diagnosis or within 1 month after diagnosis in 11 patients, and occurred 1 month or more after diagnosis in 18 patients. Twenty-nine patients (73%) had venous thrombosis and 11 (28%) had arterial thrombosis. Eight patients (20%) died within 1 month after the thrombotic event, and 18 (45%) died within 1 year. The development of thrombosis in patients with AL amyloidosis appears to predict significant mortality within the first month and year after the event.

Entities:  

Mesh:

Year:  2006        PMID: 16690498     DOI: 10.1080/13506120500537285

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  4 in total

1.  Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.

Authors:  Carrie A Thompson; Robert Kyle; Morie Gertz; John Heit; Rajiv Pruthi; Animesh Pardanani
Journal:  Am J Hematol       Date:  2010-03       Impact factor: 10.047

2.  Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.

Authors:  Katherine M Bever; Luke I Masha; Fangui Sun; Lauren Stern; Andrea Havasi; John L Berk; Vaishali Sanchorawala; David C Seldin; J Mark Sloan
Journal:  Haematologica       Date:  2015-10-09       Impact factor: 9.941

3.  Acute limb ischemia in a patient with cardiac amyloidosis: a case report.

Authors:  Christos Verikokos; Marika Moschou; Evridiki Karanikola; Stephanie Vgenopoulou; John Bellos; Panagiotis Roukanas; Efthimios Avgerinos
Journal:  Cases J       Date:  2009-09-08

Review 4.  Hematological Malignancies and Arterial Thromboembolism.

Authors:  Nathan Visweshwar; Michael Jaglal; Lubomir Sokol; Benjamin Djulbegovic
Journal:  Indian J Hematol Blood Transfus       Date:  2019-01-28       Impact factor: 0.900

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.